Zimmer Biomet Holdings, Inc. (ZBH)

Market Cap	24.91B
Revenue (ttm)	7.45B
Net Income (ttm)	963.90M
Shares Out	205.73M
EPS (ttm)	4.61
PE Ratio	26.02
Forward PE	14.48
Dividend	$0.96 (0.79%)
Ex-Dividend Date	Jun 26, 2024

Volume	80,787
Open	120.58
Previous Close	119.97
Day's Range	120.48 - 121.15
52-Week Range	102.00 - 147.50
Beta	1.03
Analysts	Buy
Price Target	138.53 (+14.45%)
Earnings Date	May 2, 2024

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1927
• Employees: 18,000
• Stock Exchange: NYSE
• Ticker Symbol: ZBH

Financial Performance

In 2023, ZBH's revenue was $7.39 billion, an increase of 6.55% compared to the previous year's $6.94 billion. Earnings were $1.02 billion, an increase of 342.52%.

Analyst Forecast

According to 16 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price forecast is $138.53, which is an increase of 14.45% from the latest price.

Price Target

$138.53

(14.45% upside)

Analyst Consensus: Buy